Future Science Group
Browse
1/1
11 files

Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland - supplementary material

dataset
posted on 2023-08-02, 09:05 authored by Simone Critchlow, Ash Bullement, Simon Crabb, Robert Jones, Katerina Christoforou, Amerah Amin, Ying Xiao, Venediktos Kapetanakis, A´ gnes Benedict, Jane Chang, Mairead Kearney, Anthony Eccleston

Figure S1. Model schematic.

Curves provided in this image are hypothetical to illustrate how health state occupancy is determined. OS: overall survival; PD: progressed disease; PF: progression free; PFS: progression-free survival.

Figure S2. Parametric survival model extrapolations for OS (avelumab + BSC). BSC: best supportive care; KM: Kaplan-Meier; OS: overall survival.

Figure S3. Parametric survival model extrapolations for OS (BSC). BSC: best supportive care; KM: Kaplan-Meier; OS: overall survival.

Figure S4. Log-cumulative hazard plot for OS. BSC: best supportive care; OS: overall survival.

Figure S5. Standard parametric survival model extrapolations for PFS (avelumab + BSC). BSC: best supportive care; KM: Kaplan-Meier; PFS: progression-free survival.

Figure S6. Standard parametric survival model extrapolations for PFS (BSC). BSC: best supportive care; KM: Kaplan-Meier; PFS: progression-free survival.

Figure S7. Spline-based parametric survival model extrapolations for PFS (avelumab + BSC). BSC: best supportive care; KM: Kaplan-Meier; PFS: progression-free survival.

Figure S8. Spline-based parametric survival model extrapolations for PFS (BSC). BSC: best supportive care; KM: Kaplan-Meier; PFS: progression-free survival.

Figure S9. Log-cumulative hazard plot for PFS. BSC: best supportive care; PFS: progression-free survival.

Figure S10. Extrapolations for TTD (avelumab + BSC). BSC: best supportive care; KM: Kaplan-Meier; TTD: time to treatment discontinuation.

Table S1. Statistical goodness-of-fit scores for OS.

Table S2. Statistical goodness-of-fit scores for PFS.

Table S3. Model parameters.


Funding

Pfizer, (Grant / Award Number: ) the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945) , (Grant / Award Number: )

History

Usage metrics

    Future Oncology

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC